Innoviva, Inc. (INVA)
22.03
-0.15
(-0.68%)
USD |
NASDAQ |
Mar 06, 16:00
22.04
+0.01
(+0.05%)
After-Hours: 20:00
Innoviva Cash from Investing (Quarterly) : 23.64M for Dec. 31, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Merck & Co., Inc. | -11.20B |
| Nektar Therapeutics | -94.87M |
| Regeneron Pharmaceuticals, Inc. | 220.30M |
| Oramed Pharmaceuticals, Inc. | 38.82M |
| Theravance Biopharma, Inc. | -100.25M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 54.51M |
| Cash from Financing (Quarterly) | -3.721M |
| Free Cash Flow | 195.80M |
| Free Cash Flow Per Share (Quarterly) | 0.6392 |
| Free Cash Flow to Equity (Quarterly) | 44.45M |
| Free Cash Flow to Firm (Quarterly) | 57.29M |
| Free Cash Flow Yield | 11.20% |